[go: up one dir, main page]

WO2001034202A3 - Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells - Google Patents

Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells Download PDF

Info

Publication number
WO2001034202A3
WO2001034202A3 PCT/US2000/031068 US0031068W WO0134202A3 WO 2001034202 A3 WO2001034202 A3 WO 2001034202A3 US 0031068 W US0031068 W US 0031068W WO 0134202 A3 WO0134202 A3 WO 0134202A3
Authority
WO
WIPO (PCT)
Prior art keywords
depletion
cancer cells
coa
levels
kill cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/031068
Other languages
French (fr)
Other versions
WO2001034202A2 (en
Inventor
Ellen S Pizer
Craig A Townsend
Francis P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to JP2001536199A priority Critical patent/JP2003516938A/en
Priority to EP00977179A priority patent/EP1235568A2/en
Priority to AU14854/01A priority patent/AU1485401A/en
Priority to KR1020027006104A priority patent/KR20020060737A/en
Priority to CA002390501A priority patent/CA2390501A1/en
Publication of WO2001034202A2 publication Critical patent/WO2001034202A2/en
Publication of WO2001034202A3 publication Critical patent/WO2001034202A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention describes a method to inhibit growth or kill cancer cells by acute depletion of free cellular Coenzyme A (CoA). This invention encompasses: any method to selectively decrease CoA in cancer cells by increasing the utilization of CoA and/or reducing its synthesis. As demonstrated herein, depletion of free CoA may be accomplished by inhibiting fatty acid synthase (FAS). This invention also includes depletion of free cellular Coenzyme A by interventions in addition to or alternative to FAS inhibition.
PCT/US2000/031068 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells Ceased WO2001034202A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001536199A JP2003516938A (en) 1999-11-12 2000-11-13 Method for selectively killing cancer cells by reducing cellular coenzyme A level
EP00977179A EP1235568A2 (en) 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
AU14854/01A AU1485401A (en) 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
KR1020027006104A KR20020060737A (en) 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
CA002390501A CA2390501A1 (en) 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16474999P 1999-11-12 1999-11-12
US60/164,749 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034202A2 WO2001034202A2 (en) 2001-05-17
WO2001034202A3 true WO2001034202A3 (en) 2002-04-18

Family

ID=22595935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031068 Ceased WO2001034202A2 (en) 1999-11-12 2000-11-13 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells

Country Status (6)

Country Link
EP (1) EP1235568A2 (en)
JP (1) JP2003516938A (en)
KR (1) KR20020060737A (en)
AU (1) AU1485401A (en)
CA (1) CA2390501A1 (en)
WO (1) WO2001034202A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200500745A1 (en) * 2002-10-31 2005-12-29 Фасджен, Ллс. METHOD OF INHIBITING THE DEVELOPMENT OF MALIGNANT TUMORS BY FAT ACIDS SYNTHASE INHIBITORS
CN105530940A (en) 2013-09-12 2016-04-27 辉瑞大药厂 Use of acetyl-CoA carboxylase inhibitors for the treatment of acne vulgaris

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HENNIGAR RANDOLPH A ET AL: "Characterization of fatty acid synthase in cell lines derived from experimental mammary tumors.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1392, no. 1, 20 May 1998 (1998-05-20), pages 85 - 100, XP000942091, ISSN: 0006-3002 *
KUHAJDA, F. P. (1) ET AL: "Synthesis and anti- tumor activity of a novel inhibitor of fatty acid synthase.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 121. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN, XP000942089 *
PIZER E S ET AL: "Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells.", CANCER RESEARCH, (1996 FEB 15) 56 (4) 745-51., XP000942096 *
PIZER ELLEN S ET AL: "Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells.", CANCER RESEARCH, vol. 56, no. 12, 1996, pages 2745 - 2747, XP000942097, ISSN: 0008-5472 *
PIZER ELLEN S ET AL: "Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty acid synthase inhibition in human breast cancer cell and xenografts.", CANCER RESEARCH, vol. 60, 15 January 2000 (2000-01-15), pages 213 - 218, XP000983309, ISSN: 0197-016X *

Also Published As

Publication number Publication date
EP1235568A2 (en) 2002-09-04
JP2003516938A (en) 2003-05-20
AU1485401A (en) 2001-06-06
WO2001034202A2 (en) 2001-05-17
CA2390501A1 (en) 2001-05-17
KR20020060737A (en) 2002-07-18

Similar Documents

Publication Publication Date Title
WO2000071703A3 (en) Inhibition of histone deacetylase
WO2005051358A8 (en) Composition and method for enhancing bioavailability
WO1999040087A3 (en) Inhibition of human telomerase by a g-quadruplex-interaction compound
WO2005003320A3 (en) Neuronal differentiation of stem cells
IL236013A (en) Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
WO1999042080A3 (en) Curable compositions with antimicrobial properties
WO2003062394A3 (en) Methods and compositions for rna interference
AP2005003199A0 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
WO2006015159A3 (en) Potassium channel inhibitors
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
HK1052346A1 (en) Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
WO2004053101A3 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
WO1999052543A3 (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
WO2002060914A3 (en) Identification of small rnas and orfs form e. coli as mediators of cell and intercell regulation
WO2000033887A3 (en) Methods and formulations for reducing circulating antibodies
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
WO2005062957A3 (en) Compositions and methods for combined therapy of disease
AU2002239258A1 (en) Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
WO2001034202A3 (en) Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
WO2004003152A3 (en) Sos1 inhibitors
WO2006012594A3 (en) Modification of lignin biosynthesis
WO2002004598A3 (en) Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase
AU6558100A (en) Enzymatic method for killing or inhibiting microbial cells at high ph
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 14854/01

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000977179

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2390501

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536199

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10129848

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020027006104

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 519229

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020027006104

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000977179

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000977179

Country of ref document: EP